Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, Kabil K, Hassany M, Shawky A, Yosry A, Shaker MK, ElShazly Y, Waked I, Esmat G, Doss W. El-Akel W, et al. Among authors: elshazly y. J Viral Hepat. 2017 Apr;24(4):262-267. doi: 10.1111/jvh.12668. Epub 2017 Feb 1. J Viral Hepat. 2017. PMID: 28145032 Review.
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
Elsharkawy A, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, Said M, Motawea I, El Demerdash T, Seif S, Gaballah A, El Shazly Y, Makhlouf MA, Waked I, Abdelaziz AO, Yosry A, El Serafy M, Thursz M, Doss W, Esmat G. Elsharkawy A, et al. Aliment Pharmacol Ther. 2017 Mar;45(5):681-687. doi: 10.1111/apt.13923. Epub 2017 Jan 9. Aliment Pharmacol Ther. 2017. PMID: 28070899
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Omar H, et al. Aliment Pharmacol Ther. 2018 Feb;47(3):421-431. doi: 10.1111/apt.14428. Epub 2017 Nov 29. Aliment Pharmacol Ther. 2018. PMID: 29193226
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Elbaz T, et al. Among authors: elshazly y. J Interferon Cytokine Res. 2017 Aug;37(8):348-353. doi: 10.1089/jir.2016.0131. J Interferon Cytokine Res. 2017. PMID: 28777714
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
El-Sayed M, Elserafy M, El Raziky M, Elakel W, Saad Y, Fayad T, Korany M, Mehrez M, Salama R, Mahrous M, Zaki A, Hassany M, Ammar I, Elsaeed K, Elshazly Y, Doss W. El-Sayed M, et al. Among authors: elshazly y. Arab J Gastroenterol. 2023 Feb;24(1):29-33. doi: 10.1016/j.ajg.2022.10.001. Epub 2023 Feb 20. Arab J Gastroenterol. 2023. PMID: 36813580
Seroprevalence of HBV/HCV coinfection among patients with HCV screened during the national campaign for HCV eradication in Egypt.
Gamal Eldeen H, Hassany M, Elakel W, AbdAllah M, Abdel-Razek W, Elshazly Y, Dabbous HM, Hamdy El-Sayed M, El-Serafy M, Waked I, Esmat G, Doss W, Hashem A. Gamal Eldeen H, et al. Among authors: elshazly y. Arab J Gastroenterol. 2022 Nov;23(4):259-262. doi: 10.1016/j.ajg.2022.06.006. Epub 2022 Nov 3. Arab J Gastroenterol. 2022. PMID: 36336587
22 results